Infectious Disease

Collaboration is part of a citywide plan to ensure patients with HIV receive care and to reduce the number of new HIV transmissions.

Study provides picture of host cell pathway mobilization to HCV.

Non-EU and EEA countries trail behind in reaching viral suppression target by 2020.

The criminalization of drug use could be detrimental to HIV patient health and does not decrease use, study suggests.

Patient-reported allergy to penicillin antibiotics is a common scenario during health care encounters, with an estimated population prevalence of roughly 8% to 12%.

Investing in diagnostic resources, prevention, and treatment programs are vital to ending the HIV epidemic in the United States.

Top news of the day from across the health care landscape.

The study is the first to demonstrate that CRISPR/Cas9 technology may lead to an HIV cure.

Positivity interventions may influence health outcomes in people living with HIV.

The vending machines dispense kits containing sterile syringes and needles in hopes of reducing the spread of infectious disease.

Predicting the evolution of HIV surface proteins could be used to develop better vaccines.

Hypermutated HIV suppresses immune response.

Glecaprevir/pibrentasvir achieved 99% sustained virologic response rate in patients with chronic HCV with compensated cirrhosis.

Experimental glecaprevir/pibrentasvir treatment shows efficacy across hepatitis C genotypes.

The rise of antibiotic-resistant organisms poses a great threat to national health.

Decline in cancer incidence rates most likely driven by modern antiretroviral therapies.

The final part of a 4-part interview with an infectious disease expert examines the furture treatment landscape and caring for an aging HIV population.

The third of a 4-part interview with an infectious disease expert discusses the impact of specialty drugs and the potential loss of funding to HIV treatment programs.

Regulating emotion may help reduce the risk of HIV spreading among high-risk populations.

Novel therapeutic approach may help cure patients with HIV in the future.

The second of 4-part interview with an infectious disease expert examines weighing the short-term high cost of treating HCV with curative drugs versus the long-term costs of treating the disease.

Mark Wainberg, PhD was an influential researcher from the start of the AIDS epidemic.

Part 1 of a 4-part interview with an infectious disease expert explores treatment advances in HIV since the AIDS epidemic in the 1980s.

Novel drug delivery system steadily releases preventive HIV drugs over an extended period of time.

Top news of the day from across the healthcare landscape.

Technique will help scientists develop an effective HIV vaccine.

Poorer health outcomes found in perinatally HIV-infected youth.

New tuberculosis cases have declined over the past 5 years, but new data show rates are up for TB/HIV coinfections.

Adults who receive vaccination reimbursement through an employer-sponsored pharmacy insurance benefit may be more likely to receive vaccinations, according to data revealed in a poster presentation at the American Pharmacists Association (APhA) 2017 Annual Meeting & Exposition in San Francisco.

Marker helps differentiate dormant HIV-infected cells from their health counterpart cells.